Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion type Assertion NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_head.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion evidence source_evidence_literature NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion SIO_000772 25499080 NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion wasDerivedFrom befree-2016 NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion wasGeneratedBy ECO_0000203 NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.